¼¼°èÀÇ gRNA(°¡À̵å RNA) ½ÃÀå
gRNA
»óǰÄÚµå : 1774886
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 475 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

gRNA(°¡À̵å RNA) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 16¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 5¾ï 7,290¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â gRNA ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 18.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 16¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. gRNA ÃÖÁ¾ Á¦Ç°Àº ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß Çϳª·Î CAGRÀº 18.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 9¾ï 7,720¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. gRNA ÇÕ¼º Á¦Ç° ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 20.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 5,610¸¸ ´Þ·¯, Áß±¹Àº CAGR 24.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ gRNA ½ÃÀåÀº 2024³â¿¡ 1¾ï 5,610¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 3¾ï 5,290¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 24.2%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, °¢°¢ ºÐ¼® ±â°£ µ¿¾È¿¡ 13.8%¿Í 16.6%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 14.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è gRNA ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

CRISPR À¯ÀüÀÚ ÆíÁýÀÇ º¸±ÞÀ¸·Î gRNA ½ÃÀå È®´ë?

CRISPR-Cas9 ±â¼úÀÇ µîÀåÀº À¯ÀüÀÚ ÆíÁý¿¡ Çõ¸íÀ» °¡Á®¿Ô°í, °¡À̵å RNA(gRNA) ½ÃÀåÀÇ Å« ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. gRNA´Â CRISPR º£À̽ºÀÇ À¯ÀüÀÚ ÆíÁý ½Ã½ºÅÛÀÇ Áß¿äÇÑ ±¸¼º¿ä¼ÒÀ̸ç, Cas9 È¿¼Ò¸¦ ƯÁ¤ À¯ÀüÀÚ ¼­¿­¿¡ À¯µµÇÏ¿© Á¤È®ÇÑ º¯ÇüÀ» ¼öÇàÇÕ´Ï´Ù. À¯ÀüÀÚ ¿¬±¸, ³ó¾÷, Ä¡·áÁ¦ °³¹ß¿¡ CRISPR ±â¼úÀÇ Àû¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °íǰÁúÀÇ ¸ÂÃãÇü gRNA ºÐÀÚ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº ÇÕ¼º ¹× ½ÃÇè°ü ³» Àü»ç gRNA¸¦ Ȱ¿ëÇÏ¿© ÆíÁý È¿À²À» ³ôÀ̰í, ¿ÀÇÁ Ÿ°Ù È¿°ú¸¦ ÁÙÀ̰í, À¯ÀüÀÚ º¯ÇüÀÇ Á¤È®µµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿°±â±³Á¤ ¹× ÇÁ¶óÀÓ ÆíÁý°ú °°Àº Â÷¼¼´ë À¯ÀüÀÚ ÆíÁý ½Ã½ºÅÛÀÇ ÃâÇöÀ¸·Î ÷´Ü ºÐÀÚ»ý¹°ÇÐÀû ÀÀ¿ë¿¡¼­ gRNAÀÇ ¿ªÇÒÀÌ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿ÀÇÁŸ°Ù Ȱ¼º, À±¸®Àû ¹®Á¦, ±ÔÁ¦Àû ¹®Á¦ µîÀÇ °úÁ¦´Â ¿©ÀüÈ÷ ³²¾ÆÀÖÁö¸¸, CRISPR ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀº ÃÖÀûÈ­µÈ °íÃæ½Çµµ gRNA ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

AI¿Í °è»ê»ý¹°ÇÐÀº ¾î¶»°Ô gRNA ¼³°è¸¦ °­È­Çϴ°¡?

ÀΰøÁö´É(AI)°ú °è»ê»ý¹°ÇÐÀº gRNA ¼³°è¿¡ º¯È­¸¦ °¡Á®¿Í Ç¥Àû ƯÀ̼ºÀ» Çâ»ó½Ã۰í ÀǵµÇÏÁö ¾ÊÀº µ¹¿¬º¯À̸¦ °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù. ±â°èÇнÀ ¾Ë°í¸®ÁòÀº ¿ÀÇÁŸ°Ù È¿°ú¸¦ ÃÖ¼ÒÈ­ÇÑ ÃÖÀûÀÇ gRNA ¼­¿­À» ¿¹ÃøÇϱâ À§ÇØ Ã¤ÅõǾî CRISPR ±â¹Ý À¯ÀüÀÚ ÆíÁýÀÇ ¼º°ø·üÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµåº£À̽ºÀÇ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Ç÷§Æû°ú À¯Àüü ¿ÍÀÌµå ½ºÅ©¸³ÆÃ ÅøÀ» ÅëÇØ ¿¬±¸ÀÚµéÀº gRNA ¼­¿­À» ºü¸£°Ô ¼³°èÇÏ°í °ËÁõÇÒ ¼ö ÀÖ¾î À¯ÀüÀÚ ¿¬±¸ ¼Óµµ°¡ »¡¶óÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, gRNA ÇÕ¼º ¹× ½ºÅ©¸®´×¿¡ AI ±â¹Ý ÀÚµ¿È­¸¦ ÅëÇÕÇÔÀ¸·Î½á »ý¸í°øÇÐ ±â¾÷ ¹× Çмú ±â°üÀÇ ºñ¿ëÀ» Àý°¨Çϰí Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀü¿¡µµ ºÒ±¸Çϰí, gRNAÀÇ È¿À²¼º ÆíÂ÷ ¹× Á¾ÇÕÀûÀÎ °ËÁõ ¿¬±¸ÀÇ Çʿ伺 µîÀÇ °úÁ¦´Â ¿©ÀüÈ÷ ³²¾ÆÀÖ½À´Ï´Ù. ±×·¯³ª AI ±â¹Ý À¯ÀüÀÚ ÆíÁý µµ±¸°¡ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó, »ý¸í°øÇÐ ¹× ÀÇ·á ºÐ¾ß¿¡¼­ÀÇ gRNA ¾ÖÇø®ÄÉÀ̼ÇÀÇ Á¤È®¼º°ú È¿À²¼ºÀÌ Å©°Ô Çâ»óµÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

gRNA°¡ Ä¡·á¿ë À¯ÀüÀÚ ÆíÁý¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖÀ»±î?

À¯ÀüÀÚ Ä¡·á¿Í ¸ÂÃãÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Ä¡·á¿ë gRNA ±â¹Ý À¯ÀüÀÚ ÆíÁý ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °â»ó ÀûÇ÷±¸Áõ, µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ, À¯Àü¼º ½Ç¸íÁõ°ú °°Àº À¯Àü¼º ÁúȯÀ» ´ë»óÀ¸·Î ÇÏ´Â CRISPR ±â¹Ý Ä¡·á´Â Áúº´À» À¯¹ßÇÏ´Â µ¹¿¬º¯À̸¦ ±³Á¤Çϱâ À§ÇØ Á¤¹ÐÇÏ°Ô ¼³°èµÈ gRNA ¼­¿­¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, gRNA´Â ¸é¿ªÄ¡·á¿¡µµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ¾Ï Ä¡·á¸¦ À§ÇÑ Àΰø T¼¼Æ÷ Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº CRISPR ±â¹Ý ½Å¾à°³¹ß¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, gRNA¸¦ ÀÌ¿ëÇØ À¯ÀüÀÚ ³ì¾Æ¿ôÀ» °³¹ßÇϰí, »õ·Î¿î Ä¡·á Ç¥ÀûÀ» ¹ß±¼Çϱâ À§ÇÑ ±â´ÉÀ¯ÀüüÇÐ ¿¬±¸¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª À¯ÀüÀÚ ÆíÁýÀÇ ¸é¿ª¹ÝÀÀ, Àü´Þ ¸ÞÄ¿´ÏÁò, Àå±âÀû ¿µÇ⠵ ´ëÇÑ ¿ì·Á°¡ ÀÓ»ó Àû¿ë¿¡ ´ëÇÑ °úÁ¦·Î ³²¾ÆÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸Çϰí, gRNAÀÇ ÃÖÀûÈ­ ¹× Àü´Þ Àü·«ÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀº Àç»ýÀÇ·á ¹× Ä¡·á¿ë À¯ÀüÀÚ ÆíÁý ºÐ¾ß¿¡¼­ º¸´Ù Æø³Ð°Ô äÅÃµÉ ¼ö ÀÖ´Â ±æÀ» ¿­¾îÁÙ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

gRNA ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº?

gRNA ½ÃÀåÀÇ ¼ºÀåÀº CRISPR À¯ÀüÀÚ ÆíÁýÀÇ ÀÀ¿ë È®´ë, AI ±â¹Ý gRNA ¼³°èÀÇ ¹ßÀü, À¯ÀüÀÚ Ä¡·á ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÇÕ¼º»ý¹°ÇÐ ¹× Á¤¹ÐÀÇ·áÀÇ ºÎ»óÀ¸·Î ¸ÂÃãÇü °íƯÀ̼º gRNA ¼­¿­¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇüÁúÀ» °­È­ÇÑ À¯ÀüÀÚ º¯Çü ÀÛ¹° °³¹ßÀ» ¸ñÀûÀ¸·Î ÇÏ´Â CRISPR ±â¹Ý ³ó¾÷ »ý¸í°øÇÐ ±â¼úÀÇ Ã¤Åà Ȯ´ë°¡ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. gRNA´Â ÇÁ¶óÀÓ ÆíÁý, ÈļºÀ¯Àüü ÆíÁý µî Â÷¼¼´ë À¯ÀüÀÚ ÆíÁý ±â¼ú¿¡ ÅëÇÕµÇ¾î »ý¸í°úÇÐ ºÐ¾ß¿¡¼­ Ȱ¾àÀÇ ÆøÀ» ´õ¿í ³ÐÇô°¡°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ºÒÈ®½Ç¼º, À±¸®Àû ¹®Á¦ µîÀÇ °úÁ¦°¡ ³²¾ÆÀÖÁö¸¸, CRISPR ±â¼úÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀº °íǰÁú gRNA¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÃÖ÷´Ü À¯ÀüÀÚ ¿¬±¸ ¹× Ä¡·á ÀÀ¿ë ºÐ¾ß¿¡¼­ gRNAÀÇ ¿ªÇÒÀ» °­È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

Á¦Ç° ¹× ¼­ºñ½º(gRNA ÃÖÁ¾ Á¦Ç°, gRNA ÇÕ¼º Á¦Ç°, Ä¿½ºÅÒ gRNA ÇÕ¼º ¼­ºñ½º), gRNA À¯Çü(¿¬±¸¿ë À¯Çü, GMP µî±Þ À¯Çü), ¿ëµµ(À¯Àüü °øÇÐ ¿ëµµ, Áúȯ ¸ðµ¨ ¿¬±¸ ¿ëµµ, ±â´ÉÀ¯ÀüüÇÐ ¿ëµµ, ÈÄ»ýÀ¯ÀüÇÐ ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾ ¿ëµµ, Çмú¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, CMO¡¤CRO ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global gRNA Market to Reach US$1.6 Billion by 2030

The global market for gRNA estimated at US$572.9 Million in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 18.5% over the analysis period 2024-2030. gRNA Final Products, one of the segments analyzed in the report, is expected to record a 18.0% CAGR and reach US$977.2 Million by the end of the analysis period. Growth in the gRNA Synthesis Products segment is estimated at 20.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$156.1 Million While China is Forecast to Grow at 24.2% CAGR

The gRNA market in the U.S. is estimated at US$156.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$352.9 Million by the year 2030 trailing a CAGR of 24.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.8% and 16.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.7% CAGR.

Global gRNA Market - Key Trends & Drivers Summarized

Is the Growing Popularity of CRISPR Gene Editing Expanding the gRNA Market?

The rise of CRISPR-Cas9 technology has revolutionized gene editing, driving significant growth in the guide RNA (gRNA) market. gRNA is a crucial component of CRISPR-based gene editing systems, directing the Cas9 enzyme to specific genetic sequences for precise modifications. The increasing application of CRISPR technology in genetic research, agriculture, and therapeutic development is fueling demand for high-quality, customizable gRNA molecules. Researchers are leveraging synthetic and in vitro-transcribed gRNA to enhance editing efficiency and reduce off-target effects, improving the precision of genetic modifications. Additionally, the emergence of next-generation gene editing systems, such as base editing and prime editing, is further expanding the role of gRNA in advanced molecular biology applications. While challenges such as off-target activity, ethical concerns, and regulatory hurdles persist, the continuous advancement of CRISPR technology is expected to drive the demand for optimized and high-fidelity gRNA solutions.

How Is AI and Computational Biology Enhancing gRNA Design?

Artificial intelligence (AI) and computational biology are transforming gRNA design, improving target specificity and reducing unintended mutations. Machine learning algorithms are being employed to predict optimal gRNA sequences with minimal off-target effects, enhancing the success rate of CRISPR-based gene editing. Cloud-based bioinformatics platforms and genome-wide screening tools are enabling researchers to rapidly design and validate gRNA sequences, accelerating the pace of genetic research. Additionally, the integration of AI-driven automation in gRNA synthesis and screening is reducing costs and increasing accessibility for biotech companies and academic institutions. Despite these technological advancements, challenges such as variability in gRNA efficiency and the need for comprehensive validation studies remain. However, as AI-powered gene editing tools continue to evolve, they are expected to significantly improve the precision and efficiency of gRNA applications in biotechnology and medicine.

Can gRNA Play a Crucial Role in Therapeutic Gene Editing?

The increasing focus on gene therapy and personalized medicine is driving demand for gRNA-based gene editing solutions in therapeutic applications. CRISPR-based treatments targeting genetic disorders such as sickle cell disease, Duchenne muscular dystrophy, and inherited blindness rely on precisely designed gRNA sequences to correct disease-causing mutations. Additionally, gRNA is playing a critical role in immunotherapy, enabling engineered T-cell therapies for cancer treatment. Pharmaceutical companies are investing in CRISPR-based drug discovery, using gRNA to develop gene knockouts and functional genomics studies for identifying novel therapeutic targets. However, concerns regarding immune responses, delivery mechanisms, and long-term effects of gene editing pose challenges for clinical translation. Despite these hurdles, the ongoing advancements in gRNA optimization and delivery strategies are expected to pave the way for broader adoption in regenerative medicine and therapeutic gene editing.

What Is Driving the Growth of the gRNA Market?

The growth in the gRNA market is driven by several factors, including the expanding applications of CRISPR gene editing, advancements in AI-driven gRNA design, and increasing investments in gene therapy research. The rise of synthetic biology and precision medicine is fueling demand for customizable and high-specificity gRNA sequences. Additionally, the growing adoption of CRISPR-based agricultural biotechnology, aimed at developing genetically modified crops with enhanced traits, is contributing to market expansion. The integration of gRNA in next-generation gene editing techniques, such as prime editing and epigenome editing, is further expanding its scope in life sciences. While challenges such as regulatory uncertainties and ethical concerns persist, continuous innovation in CRISPR technologies is expected to drive the demand for high-quality gRNA, reinforcing its role in cutting-edge genetic research and therapeutic applications.

SCOPE OF STUDY:

The report analyzes the gRNA market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Services (gRNA Final Products, gRNA Synthesis Products, Custom gRNA Synthesis Services); gRNA Type (Research-Use Type, GMP-Grade Type); Application (Genome Engineering Application, Disease Model Studies Application, Functional Genomics Application, Epigenetics Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, Academic Research Institutes End-Use, CMOs & CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â